$1.26
-0.025-1.94%
最終更新: Oct 14, 4:02 PM
$1.26
-0.03-2.33%
Benzinga
Benzinga
Benzinga
土曜日, 10 17
Benzinga
© 2026 Benzinga | All Rights Reserved
Chemomab Therapeutics (CMMB) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.08 | $-0.08 | $-0.10 | $-0.10 |
| Actual | $-0.27 | $-0.24 | $-0.24 | $-0.28 |
| Surprise | -237.5% | -200.0% | -140.0% | -180.0% |
| Revenue | ||||
| Estimate | — | — | — | — |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | — | — | — | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.04 | $-0.20 | $-0.20 | $-0.20 |
| Revenue | ||||
| Consensus | — | — | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 19, 2026 | $-0.27 | $-0.08 | -237.5 % |
| Q1 | May 14, 2026 | $-0.24 | $-0.08 | -200.0 % |
| Q4 | Mar 19, 2026 | $-0.24 | $-0.10 | -140.0 % |
| Q3 | Nov 20, 2025 | $-0.28 | $-0.10 | -180.0 % |